Search

Your search keyword '"van der Veldt, A.A.M."' showing total 149 results
Start Over Author "van der Veldt, A.A.M."
149 results on '"van der Veldt, A.A.M."'

2. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

Author

Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., and Uyl-de Groot, C.A.

Published
2021
Full Text
View/download PDF

4. From decision to reflection: Understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting

Author

Kamminga, N.C.W., van der Veldt, A.A.M., Wakkee, M., van den Berge, F.R., van der Beek, L.A.A., Joosen, M.C.W., Joosse, A., de Joode, K., Nijsten, T.E.C., Lugtenberg, M., Kamminga, N.C.W., van der Veldt, A.A.M., Wakkee, M., van den Berge, F.R., van der Beek, L.A.A., Joosen, M.C.W., Joosse, A., de Joode, K., Nijsten, T.E.C., and Lugtenberg, M.

Abstract

Background: Despite increased use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma, little is known about patient experiences during this treatment. This study aimed to gain an in-depth understanding of experiences and unmet care needs of patients treated in the adjuvant or metastatic setting for advanced melanoma regarding their ICI treatment trajectory. Methods: Interviews and focus groups were conducted among 35 patients treated with ICIs in the adjuvant setting for completely resected stage III (n = 14), or in the metastatic setting for irresectable stage IV (n = 21) melanoma. A thorough thematic content analysis was conducted.Results: Three main themes were identified. When (1) dealing with uncertainty in the decision-making process, adjuvant patients explored the pros and cons, whereas metastatic patients considered immunotherapy their only viable option. Both groups expressed the need for additional guidance. In (2) navigating the immunotherapy course, both perceived the trajectory as intense, experienced a major impact on their and their (close) relatives’ lives, and felt the need to (re)gain control. When (3) looking back on the immunotherapy experience, metastatic patients generally felt relieved, while among adjuvant patients, feelings of doubt regarding their choice for ICIs were also reported. Conclusions: ICI treatment is perceived as intensive for both patient groups, facing both comparable and distinct challenges throughout the treatment trajectory, underscoring the need for stage-specific, individualised guidance. Options regarding flexible follow-ups, low-threshold contact and psychosocial support throughout the treatment trajectory should be explored.

Published
2024

5. Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

Author

Oosting, S.F., primary, van der Veldt, A.A.M., additional, Fehrmann, R.S.N., additional, Bhattacharya, A., additional, van Binnendijk, R.S., additional, GeurtsvanKessel, C.H., additional, Dingemans, A.-M.C., additional, Smit, E.F., additional, Hiltermann, T.J.N., additional, den Hartog, G., additional, Jalving, M., additional, Westphal, T.T., additional, de Wilt, F., additional, Ernst, S.M., additional, Boerma, A., additional, van Zijl, L., additional, Rimmelzwaan, G.F., additional, Kvistborg, P., additional, van Els, C.A.C.M., additional, Rots, N.Y., additional, van Baarle, D., additional, Haanen, J.B.A.G., additional, and de Vries, E.G.E., additional

Published
2023
Full Text
View/download PDF

6. Oncological healthcare providers’ perspectives on appropriate melanoma survivorship care: A qualitative focus group study

Author

Kamminga, N.C. W., Wakkee, M., de Bruin, R.J., van der Veldt, A.A.M., Joosse, A., Reeder, S.W.I., Plaisier, P.W., Nijsten, T., Lugtenberg, M., Kamminga, N.C. W., Wakkee, M., de Bruin, R.J., van der Veldt, A.A.M., Joosse, A., Reeder, S.W.I., Plaisier, P.W., Nijsten, T., and Lugtenberg, M.

Abstract

Background: The increasing group of melanoma survivors reports multiple unmet needs regarding survivorship care (SSC). To optimise melanoma SSC, it is crucial to take into account the perspectives of oncological healthcare providers (HCPs) in addition to those of patients. The aim of this study is to gain an in-depth understanding of HCPs’ perspectives on appropriate melanoma SSC.Methods: Four online focus groups were conducted with mixed samples of oncological HCPs (dermatologists, surgeons, oncologists, oncological nurse practitioners, support counsellors and general practitioners) (total n = 23). A topic guide was used to structure the discussions, focusing on perspectives on both SSC and survivorship care plans (SCPs). All focus groups were recorded, transcribed verbatim, and subjected to an elaborate thematic content analysis. Results: Regarding SSC, HCPs considered the current offer minimal and stressed the need for broader personalised SSC from diagnosis onwards. Although hardly anyone was familiar with SCPs, they perceived various potential benefits of SCPs, such as an increase in the patients’ self-management and providing HCPs with an up-to-date overview of the patient’s situation. Perceived preconditions for successful implementation included adequate personalisation, integration in the electronic health record and ensuring adequate funding to activate and provide timely updates.Conclusions: According to HCPs there is considerable room for improvement in terms of melanoma SSC. SCPs can assist in offering personalised and broader i.e., including psychosocial SSC. Aside from personalisation, efforts should be focused on SCPs' integration in clinical practice, and their long-term maintenance.

Published
2023

7. One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

Author

van der Veldt, A.A.M., primary, Oosting, S.F., additional, Fehrmann, R.S.N., additional, GeurtsvanKessel, C.H., additional, van Binnendijk, R.S., additional, Dingemans, A.-M.C., additional, Smit, E.F., additional, Hiltermann, T.J.N., additional, den Hartog, G., additional, Jalving, M., additional, Westphal, T.T., additional, Bhattacharya, A., additional, de Wilt, F., additional, Ernst, Sophie M., additional, Boerma, A., additional, van Zijl, L., additional, Rimmelzwaan, G.F., additional, Kvistborg, P., additional, van Els, C.A.C.M., additional, Rots, N.Y., additional, van Baarle, D., additional, Haanen, J.B.A.G., additional, and de Vries, E.G.E., additional

Published
2023
Full Text
View/download PDF

8. 19P Effects of CTLA-4 single nucleotide polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma

Author

Joode, K.D., primary, Rojas Mora, A., additional, Van Schaik, R., additional, Zippelius, A., additional, Van der Veldt, A.A.M., additional, Gerard, C.L., additional, Läubli, H., additional, Michielin, O.A., additional, von Moos, R.A.F., additional, Joerger, M., additional, Levesque, M.P., additional, Aeppli, S., additional, Mangana, J., additional, Mangas, C., additional, Meyer, S., additional, Leoni-Parvex, S., additional, Mathijssen, R.H., additional, and Metaxas, Y., additional

Published
2022
Full Text
View/download PDF

9. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma

Author

van Duin, I.A.J., primary, Elias, S.G., additional, Van Den Eertwegh, F., additional, de Groot, J.W.B., additional, Blokx, W.A.M., additional, van Not, O.J., additional, Aarts, M., additional, Blank, C.U., additional, Haanen, J.B.A.G., additional, Hospers, G., additional, Piersma, D., additional, van Rijn, R.S., additional, Stevense-den Boer, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, Kapiteijn, E., additional, and Suijkerbuijk, K.P.M., additional

Published
2022
Full Text
View/download PDF

10. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Author

Versluis, J.M., primary, Elens, R., additional, Reijers, I.L.M., additional, Menzies, A.M., additional, Van der Veldt, A.A.M., additional, Kapiteijn, E., additional, Rozeman, E.A., additional, Klop, M.C., additional, Van Houdt, W., additional, Saw, R.P.M., additional, Zuur, C.L., additional, Pennington, T.E., additional, van de Wiel, B., additional, Scolyer, R.A., additional, Broeks, A., additional, van Akkooi, A.C.J., additional, Long, G.V., additional, and Blank, C.U., additional

Published
2022
Full Text
View/download PDF

11. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma

Author

van Not, O.J., primary, Van Den Eertwegh, F., additional, Haanen, J.B.A.G., additional, van Rijn, R.S., additional, Aarts, M., additional, Van den Berkmortel, F., additional, Blank, C.U., additional, Boers-Sonderen, M., additional, de Groot, J.W.B., additional, Hospers, G., additional, Kapiteijn, E., additional, De Meza, M.M., additional, Piersma, D., additional, Stevense-den Boer, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M., additional, Blokx, W.A.M., additional, and Suijkerbuijk, K.P.M., additional

Published
2022
Full Text
View/download PDF

12. 860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma

Author

de Joode, K., primary, Suijkerbuijk, K.P.M., additional, de Groot, J.W.B., additional, Van der Veldt, A.A.M., additional, Westgeest, H.M., additional, de Wijn, R., additional, Hurkmans, D.P., additional, van den Heuvel, D.M.A., additional, Schmidt, K., additional, van Doorn, T., additional, Pinedo, H.M., additional, Groten, J.P., additional, Verdegaal, E.M.E., additional, van der Burg, S.H., additional, Aerts, J.G., additional, Debets, R., additional, Kapiteijn, E., additional, and Mathijssen, R.H., additional

Published
2022
Full Text
View/download PDF

13. 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Author

Reijers, Dimitriadis, P., Traets, J.J., Saw, R., Versluis, J.M., Pennington, T., Kapiteijn, E., Van der Veldt, A.A.M., Suijkerbuijk, K., Hospers, G., Van Houdt, W., Broeks, A., Cornelissen, S., Spillane, A., Scolyer, R., van de Wiel, B., Menzies, A.M., van Akkooi, A.C.J., Long, G.V., and Blank, C.U.

Published
2022
Full Text
View/download PDF

14. The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies

Author

de Joode, K., primary, van de Geer, W.S., additional, van Leenders, G.J.L.H., additional, Hamberg, P., additional, Westgeest, H.M., additional, Beeker, A., additional, Oosting, S.F., additional, van Rooijen, J.M., additional, Beerepoot, L.V., additional, Labots, M., additional, Mathijssen, R.H.J., additional, Lolkema, M.P., additional, Cuppen, E., additional, Sleijfer, S., additional, van de Werken, H.J.G., additional, and van der Veldt, A.A.M., additional

Published
2022
Full Text
View/download PDF

15. 31P Genomic landscape and actionable targets as identified by whole genome sequencing and RNA sequencing in patients with advanced renal cell carcinoma

Author

Joode, K.D., primary, van de Geer, W.S., additional, van Leenders, G.J.L.H., additional, Hamberg, P., additional, Westgeest, H.M., additional, Beeker, A., additional, Oosting, S.F., additional, van Rooijen, J.M., additional, Beerepoot, L.V., additional, Labots, M., additional, Mathijssen, R.H., additional, Lolkema, M.P., additional, Cuppen, E., additional, Sleijfer, S., additional, van de Werken, H.J.G., additional, and Van der Veldt, A.A.M., additional

Published
2021
Full Text
View/download PDF

16. Survival of stage IV melanoma in Belgium and the Netherlands

Author

Suijkerbuijk, K.P.M., primary, Haanen, J.B.A.G., additional, Boers‐Sonderen, M.J., additional, Hospers, G.A.P., additional, Blank, C.U., additional, van den Berkmortel, F.W.P.J., additional, de Groot, J.W.B., additional, Piersma, D., additional, Aarts, M.J.B., additional, van Rijn, R.S., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Kapiteijn, E., additional, van der Veldt, A.A.M., additional, and van den Eertwegh, A.J.M., additional

Published
2021
Full Text
View/download PDF

17. 1499P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab: Week 60 update of the PRADO trial

Author

Van Den Heuvel, N.M.J., primary, Reijers, I.L.M., additional, Versluis, J.M., additional, Rozeman, E.A., additional, Saw, R.P.M., additional, Blommers, K.H., additional, Józwiak, K., additional, Suijkerbuijk, K., additional, Kapiteijn, E., additional, Van der Veldt, A.A.M., additional, Hospers, G.A., additional, Spillane, A.J., additional, Pennington, T.E., additional, Wouters, M.W.J.M., additional, Menzies, A.M., additional, van Akkooi, A.C.J., additional, Van De Poll-Franse, L.V., additional, Long, G.V., additional, Blank, C.U., additional, and Boekhout, A.H., additional

Published
2021
Full Text
View/download PDF

18. 1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment

Author

Basak, E.A., primary, Vermeer, N.S., additional, Joode, K.D., additional, Hurkmans, D.P., additional, Velthuis, D.E.M., additional, Oomen-de Hoop, E., additional, Schreurs, M.W.J., additional, Bins, S., additional, van der Leest, C., additional, Joosse, A., additional, Koolen, S.L., additional, Debets, R., additional, van der Veldt, A.A.M., additional, Aerts, J.G., additional, and Mathijssen, R.H., additional

Published
2021
Full Text
View/download PDF

19. 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma

Author

Robert, C., primary, Schadendorf, D., additional, Long, G.V., additional, Ascierto, P., additional, Intagliata, S., additional, Meier, F., additional, van der Veldt, A.A.M., additional, Ribas, A., additional, Weber, J.S., additional, Stenson, L., additional, Solovieff, N., additional, Louveau, A-L., additional, Boran, A.D., additional, Grob, J.J., additional, and Dummer, R., additional

Published
2021
Full Text
View/download PDF

20. 1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands

Author

Breeschoten, J.V., primary, Van den Eertwegh, A.J.M., additional, de Wreede, L., additional, Hilarius, D., additional, van Zwet, E., additional, Haanen, J.B.A.G., additional, Blank, C.U., additional, Aarts, M., additional, Van den Berkmortel, F., additional, de Groot, J.W.B., additional, Hospers, G.A., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Stevense, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Boers-Sonderen, M., additional, Suijkerbuijk, K., additional, and Wouters, M.W.J.M., additional

Published
2021
Full Text
View/download PDF

21. 1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality

Author

De Meza, M.M., primary, Ismail, R., additional, Blokx, W.A.M., additional, Blank, C.U., additional, Van den Eertwegh, A.J.M., additional, Aarts, M., additional, van Akkooi, A.C.J., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, Kapiteijn, E., additional, de Groot, J.W.B., additional, Haanen, J.B.A.G., additional, Hospers, G.A., additional, Piersma, D., additional, van Rijn, R.S., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Suijkerbuijk, K., additional, and Wouters, M.W.J.M., additional

Published
2021
Full Text
View/download PDF

22. LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors

Author

Oosting, S., primary, Van der Veldt, A.A.M., additional, GeurtsvanKessel, C.H., additional, Fehrmann, R.S.N., additional, van Binnendijk, R.S., additional, Dingemans, A-M.C., additional, Smit, E.F.F., additional, Hiltermann, T.J.N., additional, den Hartog, G., additional, Jalving, M., additional, Westphal, T., additional, Battacharya, A., additional, van der Heiden, M., additional, Blank, C.U., additional, Koopmans, M.P., additional, van Els, C.A., additional, Rots, N.Y., additional, van Baarle, D., additional, Haanen, J.B.A.G., additional, and de Vries, E.G., additional

Published
2021
Full Text
View/download PDF

27. 1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival

Author

Verheijden, R.J., Janssen, J.C., Putker, A.E., Veenstra, S.P.G.R., Hospers, G.A.P., Aarts, M.J.B., Hehenkamp, K.W., Doornebosch, V.L.E., Verhaert, M., Van den Berkmortel, F.W.P.J., Burgers, F.H., Haanen, J.B.A.G., Piersma, D., Kapiteijn, E., Labots, M., Boers-Sonderen, M.J., Van der Veldt, A.A.M., Aspeslagh, S., May, A.M., and Suijkerbuijk, K.P.M.

Published
2023
Full Text
View/download PDF

29. 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Author

Reijers, I., Dimitriadis, P., Menzies, A.M., Kapiteijn, E., Van der Veldt, A.A.M., Suijkerbuijk, K.P.M., Hospers, G.A.P., Van Houdt, W., Saw, R., Broeks, A., Cornelissen, S., Grijpink-Ongering, L., Pennington, T., Colebatch, A., van de Wiel, B., Scolyer, R., van Akkooi, A.C.J., Long, G.V., and Blank, C.U.

Published
2023
Full Text
View/download PDF

31. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry

Author

van Zeijl, M.C.T., primary, de Wreede, L.C., additional, van den Eertwegh, A.J.M., additional, Wouters, M.W.J.M., additional, Jochems, A., additional, Schouwenburg, M.G., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, de Groot, J.W.B., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, ten Tije, A.J., additional, van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, van der Hoeven, J.J.M., additional, and Haanen, J.B.A.G., additional

Published
2021
Full Text
View/download PDF

32. Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery

Author

de Joode, K. (Karlijn), de Ruig-Spakman, J.I. (Jolanda I.), Baktawar, S.S. (Sarwan S.), Leenders, G.J.H.L. (Geert), Verhagen, P.C.M.S. (Paul), van der Veldt, A.A.M. (Astrid A.M.), de Joode, K. (Karlijn), de Ruig-Spakman, J.I. (Jolanda I.), Baktawar, S.S. (Sarwan S.), Leenders, G.J.H.L. (Geert), Verhagen, P.C.M.S. (Paul), and van der Veldt, A.A.M. (Astrid A.M.)

Published
2020
Full Text
View/download PDF

33. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M. (Hans), Beerepoot, L.V. (Laurens), van den Berkmortel, F.W.P., Mutsaers, P.G.N.J. (Pim), van Diemen, N.G.J., Visser, O.J., Oomen-de Hoop, E., Bloemendal, H.J. (Haiko), van Laarhoven, HW, Hendriks, L.E.L., Haanen, J.B. (John), de Vries, E.G., Dingemans, A.M.A., van der Veldt, A.A.M., Loenhout, C.J. (Keetie) van, van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, BE, van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P. (Paul), Libourel, E.J. (Eduard), Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C. (Jan), Heller, R., de Groot, J.W.H., Stigt, JA, Nuij, V.J.A.A. (Veerle), Pitz, C.C.M., Slingerland, M. (Marije), Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C.V., Aarts, M.J.B. (Maureen), van Putten, J.W.G., Youssef, M., Cirkel, G.A. (Geert), Herder, G.J., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H., Claessens, N.J.M., Faber, LM, Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H. (Karin), Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M. (Karin), van Lindert, A.S.R., de Wouw, A.J.V., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P. (G.), de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M. (Hans), Beerepoot, L.V. (Laurens), van den Berkmortel, F.W.P., Mutsaers, P.G.N.J. (Pim), van Diemen, N.G.J., Visser, O.J., Oomen-de Hoop, E., Bloemendal, H.J. (Haiko), van Laarhoven, HW, Hendriks, L.E.L., Haanen, J.B. (John), de Vries, E.G., Dingemans, A.M.A., van der Veldt, A.A.M., Loenhout, C.J. (Keetie) van, van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, BE, van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P. (Paul), Libourel, E.J. (Eduard), Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C. (Jan), Heller, R., de Groot, J.W.H., Stigt, JA, Nuij, V.J.A.A. (Veerle), Pitz, C.C.M., Slingerland, M. (Marije), Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C.V., Aarts, M.J.B. (Maureen), van Putten, J.W.G., Youssef, M., Cirkel, G.A. (Geert), Herder, G.J., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H., Claessens, N.J.M., Faber, LM, Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H. (Karin), Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M. (Karin), van Lindert, A.S.R., de Wouw, A.J.V., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., and Bootsma, G.P. (G.)

Abstract

Aim of the study: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients’ characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age 65 years (p < 0.001), male gender (p Z 0.035), prior or other malignancy (p Z 0.045) and active diagnosis of haematological malignancy (p Z 0.046) or lung cancer (p Z 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (65 years). Conclusion: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered

Published
2020
Full Text
View/download PDF

34. Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151–6: Active Surveillance in Metastatic Renal Cell Cancer: M

Author

de Joode, K. (Karlijn), van der Veldt, A.A.M. (Astrid A.M.), de Joode, K. (Karlijn), and van der Veldt, A.A.M. (Astrid A.M.)

Published
2020
Full Text
View/download PDF

35. Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy

Author

Blankenstein, S.A. (Stephanie A.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Eertwegh, A.J.M. (Fons) van den, Franken, M.G. (Margreet), Groot, J.W.B. (Jan Willem) de, Haanen, J.B. (John), Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), Van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, Van Der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Wouters, M.W.J.M. (Michel), Akkooi, A.C.J. (Alexander) van, Blankenstein, S.A. (Stephanie A.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Eertwegh, A.J.M. (Fons) van den, Franken, M.G. (Margreet), Groot, J.W.B. (Jan Willem) de, Haanen, J.B. (John), Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), Van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, Van Der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Wouters, M.W.J.M. (Michel), and Akkooi, A.C.J. (Alexander) van

Abstract

Opportunities for surgical treatment in metastatic melanoma patients have re-emerged due to the development of novel systemic therapeutics over the past decade. The aim of this study is to present data on outcomes of surgery in patients with unresectable stage IIIC and IV melanoma, who have previously been treated with immunotherapy or targeted therapy. Data was extracted from the Dutch Melanoma Treatment Registry (DMTR) on 154 patients obtaining disease control to systemic therapy and undergoing subsequent surgery. Disease control was defined as a complete response (CR), which was seen in 3.2% of patients; a partial response (PR), seen in 46.1% of patients; or stable disease (SD), seen in 44.2% of patients. At a median follow-up of 10.0 months (interquartile range 4-22) after surgery, the median overall survival (OS) had not been reached in our cohort and median progression-free survival (PFS) was 9.0 months (95% CI 6.3-11.7). A CR or PR at first follow-up after surgery was associated with both a better OS and PFS compared to stable or progressive disease (p < 0.001). We conclude that selected patients can benefit from surgery after achieving disease control with systemic therapy.

Published
2020
Full Text
View/download PDF

36. Real-world outcomes of advanced melanoma patients not represented in phase III trials

Author

van Zeijl, M.C.T. (Michiel C. T.), Ismail, R.K. (Rawa K.), de Wreede, L.C. (Liesbeth C.), van den Eertwegh, A.J.M. (Alfonsus J. M.), De Boer, A. (Anthonius), van Dartel, M. (Maaike), Hilarius, D.L. (Doranne L.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Groot, J.W.B. (Jan Willem) de, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, van der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Haanen, J.B.A.G. (John B. A. G.), Wouters, M.W.J.M. (Michel), van Zeijl, M.C.T. (Michiel C. T.), Ismail, R.K. (Rawa K.), de Wreede, L.C. (Liesbeth C.), van den Eertwegh, A.J.M. (Alfonsus J. M.), De Boer, A. (Anthonius), van Dartel, M. (Maaike), Hilarius, D.L. (Doranne L.), Aarts, M.J. (Mieke), Berkmortel, F.W.P.J. (Franchette) van den, Boers-Sonderen, M.J. (M.), Groot, J.W.B. (Jan Willem) de, Hospers, G.A.P. (Geke), Kapiteijn, E. (Ellen), Piersma, D. (Djura), van Rijn, R.S. (Rozemarijn S.), Suijkerbuijk, K.P.M. (Karijn P. M.), Tije, A.J. (Albert Jan) ten, van der Veldt, A.A.M. (Astrid A. M.), Vreugdenhil, G. (Gerard), Haanen, J.B.A.G. (John B. A. G.), and Wouters, M.W.J.M. (Michel)

Abstract

The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision-making. Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met ≥1 trial exclusion criteria. These criteria were derived from the KEYNOTE-006 and CHECKMATE-067/-066 phase III trials. Prognostic importance of factors associated with overall survival (OS) was assessed with the Kaplan-Meier method, Cox models, predicted OS probabilities of prognostic subgroups and a conditional inference survival tree (CIST). A nationwide population-based registry was used as data source. Of 2536 systemically treated patients with advanced melanoma, 1004 (40%) patients were ineligible for phase IIII trials. Ineligible patients had a poorer median OS (mOS) compared to eligible patients (8.8 vs 23 months). Eligibility criteria strongly associated with OS in systemically treated ineligible patients were Eastern Cooperative Oncology Group Performance Score (ECOG PS) ≥2, brain metastases (BM) and lactate dehydrogenase (LDH) of >500 U/L. Patients with ECOG PS of ≥2 with or without symptomatic BM had a predicted mOS of 6.5 and 11.3 months and a 3-year survival probability of 9.3% and 23.6%, respectively. The CIST showed the strongest prognostic covariate for survival was LDH, followed by ECOG PS. The prognosis of patients with LDH of >500 U/L is poor, but long-term survival is possible. The prognosis of ineligible patients with advanced melanoma in real-world was very heterogeneous and highly dependent on LDH value, ECOG PS and symptomatic BM.

Published
2020
Full Text
View/download PDF

37. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective

Author

de Joode, K. (K.), Dumoulin, D.W. (D. W.), Engelen, V., Bloemendal, H.J. (Haiko), Verheij, M. (Marcel), Laarhoven, H.W.M. (Hanneke) van, Dingemans, I.H. (I. H.), Dingemans, A.C. (A. C.), van der Veldt, A.A.M. (A. A.M.), de Joode, K. (K.), Dumoulin, D.W. (D. W.), Engelen, V., Bloemendal, H.J. (Haiko), Verheij, M. (Marcel), Laarhoven, H.W.M. (Hanneke) van, Dingemans, I.H. (I. H.), Dingemans, A.C. (A. C.), and van der Veldt, A.A.M. (A. A.M.)

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of patients without COVID-19. To assess the impact of this pandemic on oncological care, a nationwide survey was conducted among patients with cancer in the Netherlands. Methods: The patients' perspective on oncological care was investigated using an online survey between March 29th 2020 and April 18th 2020. The survey consisted of 20 questions on four topics: patients’ characteristics, contact with the hospital, consequences of the COVID-19 pandemic and concerns about COVID-19. Results: Five thousand three hundred two patients with cancer completed this nationwide survey. Overall, 30% of patients reported consequences for their oncological treatment or follow-up. In the majority of cases, this resulted in conversion from hospital visit to consultation by phone or video. The most frequently adjusted treatments were chemotherapy (30%) and immunotherapy (32%). Among patients with delay and discontinuation of treatment, 55% and 63% of patients, respectively, were (very) concerned about these consequences of the COVID-19 pandemic. Consequences were independent of regional differences in COVID-19 incidence. However, patients in regions with high COVID-19 incidence were significantly more concerned. Conclusion: This is the first study investigating perspectives of patients with cancer during the COVID-19 pandemic. The study demonstrates the significant impact of the COVID-19 crisis on oncological care, indicating the need for psycho-oncological support during this pandemic.

Published
2020
Full Text
View/download PDF

38. The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node–positive melanoma without the need for completion lymph node dissection

Author

Verver, D. (Daniëlle), Rekkas, A. (A.), Garbe, C. (Claus), Klaveren, D. (David) van, Akkooi, A.C.J. (Alexander) van, Rutkowski, P. (Piotr), Powell, B.W.E.M. (Barry), Robert, C. (Caroline), Testori, A. (Alessandro), Leeuwen, B.L. (B.) van, van der Veldt, A.A.M. (Astrid A.M.), Keilholz, U. (Ulrich), Stadler, R. (Rudolf), Eggermont, A.M.M. (Alexander M.M.), Verhoef, C. (Kees), Leiter, U. (Ulrike), Grunhagen, D.J. (Dirk Jan), Verver, D. (Daniëlle), Rekkas, A. (A.), Garbe, C. (Claus), Klaveren, D. (David) van, Akkooi, A.C.J. (Alexander) van, Rutkowski, P. (Piotr), Powell, B.W.E.M. (Barry), Robert, C. (Caroline), Testori, A. (Alessandro), Leeuwen, B.L. (B.) van, van der Veldt, A.A.M. (Astrid A.M.), Keilholz, U. (Ulrich), Stadler, R. (Rudolf), Eggermont, A.M.M. (Alexander M.M.), Verhoef, C. (Kees), Leiter, U. (Ulrike), and Grunhagen, D.J. (Dirk Jan)

Abstract

Purpose: Based on recent advances in the management of patients with sentinel node (SN)–positive melanoma, we aimed to develop prediction models for recurrence, distant metastasis (DM) and overall mortality (OM). Methods: The derivation cohort consisted of 1080 patients with SN-positive melanoma from nine European Organization for Research and Treatment of Cancer (EORTC) centres. Prognostic factors for recurrence, DM and OM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across centres. The models were externally validated using a prospective cohort consisting of 705 German patients with SN-positive: 473 trial participants of the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT) and 232 screened patients. A nomogram was developed for graphical presentation. Results: The final model for recurrence and the calibrated models for DM and OM included ulceration, age, SN tumour burden and Breslow thickness. The models showed reasonable calibration. The c-index for the recurrence, DM and OM model was 0.68, 0.70 and 0.70, respectively, and 0.70, 0.72 and 0.74, respectively, in external validation. The EORTC-DeCOG model identified a robust low-risk group, with all identified low-risk patients (approximately 4% of the entire population) having a 5-year recurrence probability of <25% and an overall 5-year recurrence rate of 13%. A model including information on completion lymph node dissection (CLND) showed only marginal improvement in model performance. Conclusions: The EORTC-DeCOG nomogram provides an adequate prognostic tool for patients with SN-positive melanoma, without the need for CLND. It showed consistent results across validation. The nomogram could be used for patient counselling and might aid in adjuvant therapy decision-making.

Published
2020
Full Text
View/download PDF

39. 37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis

Author

Breeschoten, J.V., primary, Wouters, M., additional, Hilarius, D., additional, Haanen, J.B.A.G., additional, Blank, C.U., additional, Aarts, M., additional, Van den Berkmortel, F., additional, de Groot, J.W., additional, Hospers, G.A., additional, Kapiteijn, E., additional, Piersma, D., additional, Van Rijn, R., additional, Suijkerbuijk, K., additional, Blokx, W.A.M., additional, Tije, A. Ten, additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Boers-Sonderen, M., additional, and van den Eertwegh, A.J.M., additional

Published
2020
Full Text
View/download PDF

40. 1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial

Author

Van Den Heuvel, N.M.J., primary, Reijers, I.L.M., additional, Versluis, J.M., additional, Rozeman, E.A., additional, Jóźwiak, K., additional, Blommers, K.H., additional, Saw, R.P.M., additional, Suijkerbuijk, K.P.M., additional, Kapiteijn, E., additional, Van der Veldt, A.A.M., additional, Hospers, G.A.P., additional, Spillane, A.J., additional, Pennington, T., additional, Wouters, M., additional, Menzies, A.M., additional, van Akkooi, A.C.J., additional, de Poll-Franse, L. van, additional, Long, G.V., additional, Blank, C.U., additional, and Boekhout, A.H., additional

Published
2020
Full Text
View/download PDF

41. 1120P Post-approval trials versus patient registries: Comparability of advanced melanoma patients with brain metastases

Author

Ismail, R., primary, Sikkes, N., additional, Wouters, M., additional, Hilarius, D., additional, Pasmooij, M., additional, van den Eertwegh, F., additional, Aarts, M., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, de Groot, J.W.B., additional, Haanen, J.B.A.G., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R., additional, Suijkerbuijk, K.P.M., additional, Tije, A.J. ten, additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, and van Dartel, M., additional

Published
2020
Full Text
View/download PDF

42. 1078MO MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma patients

Author

Bol, K., primary, Bloemendal, M., additional, van Willigen, W., additional, Schreibelt, G., additional, Bree, S. Hins-de, additional, de Goede, A., additional, Van der Veldt, A.A.M., additional, Figdor, C., additional, de Groot, J.W.B., additional, de Wilt, J., additional, Textor, J., additional, Gerritsen, W.R., additional, and De Vries, J., additional

Published
2020
Full Text
View/download PDF

44. 1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy

Author

Ismail, R., primary, de Boer, A., additional, van Dartel, M., additional, Hilarius, D., additional, van Zeijl, M., additional, van den Eertwegh, F., additional, Aarts, M., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, de Groot, J.W.B., additional, Haanen, J.B.A.G., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R., additional, Suijkerbuijk, K.P.M., additional, Tije, A.J. ten, additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, and Wouters, M., additional

Published
2020
Full Text
View/download PDF

45. 1200P Tyrosine kinase activity profiling as a predictive biomarker for clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC

Author

Joode, K.D., primary, Groen, H.J.M., additional, Van der Veldt, A.A.M., additional, Suijkerbuijk, K.P.M., additional, de Groot, J.W.B., additional, de Wijn, R., additional, Hurkmans, D.P., additional, van den Heuvel, D.M.A., additional, Schmidt, K., additional, Groten, J.P., additional, Verdegaal, E.M.E., additional, van der Burg, S.H., additional, van den Heuvel, M.M., additional, Aerts, J.G.J.V., additional, Kapiteijn, E., additional, and Mathijssen, R.H., additional

Published
2020
Full Text
View/download PDF

47. PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?

Author

Franken, M.G., primary, Leeneman, B., additional, Van Zeijl, M., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, van den Eertwegh, A.J.M., additional, de Groot, J.W.B., additional, Herbschleb, K.H., additional, van der Hoeven, J.J.M., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, ten Tije, A.J., additional, van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M.W.J.M., additional, Haanen, J.B.A.G., additional, and Uyl-de Groot, C., additional

Published
2019
Full Text
View/download PDF

48. PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

Author

Leeneman, B., primary, Franken, M.G., additional, Aarts, M.J.B., additional, van Akkooi, A.C.J., additional, van den Berkmortel, F.W.P.J., additional, van den Eertwegh, A.J.M., additional, de Groot, J.W.B., additional, Herbschleb, K.H., additional, van der Hoeven, J.J.M., additional, Hospers, G.A.P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Suijkerbuijk, K.P.M., additional, ten Tije, A.J., additional, van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M.W.J.M., additional, Haanen, J.B.A.G., additional, and Uyl-de Groot, C., additional

Published
2019
Full Text
View/download PDF

49. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Author

Verhoeff, S.R. (Sarah R.), van Es, S.C. (Suzanne C.), Boon, E. (Eline), van Helden, E. (Erik), Angus, L. (Lindsay), Elias, S.G. (Sjoerd), Oosting, S.F. (Sjoukje), Aarntzen, E.H.J.G. (Erik), Brouwers, A.H. (A.), Kwee, T.C. (Thomas C.), Heskamp, S. (Sandra), Hoekstra, O.S. (Otto), Verheul, H.M.W. (Henk), van der Veldt, A.A.M. (Astrid A. M.), Vries, E.G.E. (Elisabeth) de, Boerman, O.C. (Otto), Graaf, W.T.A. (Winette) van der, Oyen, W.J. (Wim), Herpen, C.M.L. (Carla), Verhoeff, S.R. (Sarah R.), van Es, S.C. (Suzanne C.), Boon, E. (Eline), van Helden, E. (Erik), Angus, L. (Lindsay), Elias, S.G. (Sjoerd), Oosting, S.F. (Sjoukje), Aarntzen, E.H.J.G. (Erik), Brouwers, A.H. (A.), Kwee, T.C. (Thomas C.), Heskamp, S. (Sandra), Hoekstra, O.S. (Otto), Verheul, H.M.W. (Henk), van der Veldt, A.A.M. (Astrid A. M.), Vries, E.G.E. (Elisabeth) de, Boerman, O.C. (Otto), Graaf, W.T.A. (Winette) van der, Oyen, W.J. (Wim), and Herpen, C.M.L. (Carla)

Abstract

Purpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. Methods: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured. Results: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79–88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone. Conclusions: The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results